Home › Funds › Graham Capital Management, L.P. › TVTX

Graham Capital Management, L.P. position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Graham Capital Management, L.P. reported holding 484,292 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$28.5M, representing 0.95% of its reported portfolio and ranking #18 among its reported holdings. Graham Capital Management, L.P. has disclosed TVTX holdings in 9 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)484.29K sh
Reported value held$28.52M
Portfolio Weight0.95%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Graham Capital Management, L.P.'s TVTX position evolved

Graham Capital Management, L.P. first disclosed a stake in TVTX in Q3 2023 at 16,071 shares (US$144K). The position peaked in Q2 2025 at 41,667,000 shares, worth US$39.7M. Across 9 filings, Graham Capital Management, L.P. increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 484,292 shares valued at US$28.5M — an increase of 37,596 shares quarter over quarter.. Notable position changes include a 100% trim in Q4 2024 (shares rose 3% over the following quarter), a 2057% increase in Q1 2025 (shares fell 17% over the following quarter), a 10868% increase in Q2 2025 (shares rose 61% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 16.07K $143.67K New
Q3 2024 15.50M $13.42M New
Q4 2024 17.61K $306.85K Reduce
Q1 2025 379.90K $6.81M Add
Q2 2025 41.67M $39.75M Add
Q3 2025 467.00K $11.16M Reduce
Q1 2026 16.87M $21.35M New
Q2 2026 446.70K $25.38M Reduce
Q3 2026 484.29K $28.52M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$129.8M), Kynam Capital Management, LP (US$117.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Graham Capital Management, L.P. held TVTX?

Graham Capital Management, L.P. has disclosed TVTX holdings in 9 of the last 13 reported quarters, going back to Q3 2023.

What is Graham Capital Management, L.P.'s current position in TVTX?

As of Q3 2026, Graham Capital Management, L.P. holds 484.29K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $28.52M, representing 0.95% of its reported portfolio and ranking #18.

Has Graham Capital Management, L.P. been buying or selling TVTX?

In the latest 13F filing (Q3 2026), Graham Capital Management, L.P. increased its position in TVTX. The position peaked in Q2 2025 at 41.67M shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 54 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.